Guided Therapeutics (GTHP) Total Current Liabilities (2016 - 2025)
Historic Total Current Liabilities for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $6.5 million.
- Guided Therapeutics' Total Current Liabilities rose 738.59% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year increase of 738.59%. This contributed to the annual value of $6.2 million for FY2024, which is 2798.92% up from last year.
- Latest data reveals that Guided Therapeutics reported Total Current Liabilities of $6.5 million as of Q3 2025, which was up 738.59% from $6.4 million recorded in Q2 2025.
- In the past 5 years, Guided Therapeutics' Total Current Liabilities registered a high of $9.2 million during Q1 2021, and its lowest value of $4.0 million during Q1 2023.
- In the last 5 years, Guided Therapeutics' Total Current Liabilities had a median value of $5.7 million in 2021 and averaged $5.7 million.
- As far as peak fluctuations go, Guided Therapeutics' Total Current Liabilities crashed by 4095.79% in 2022, and later surged by 3344.99% in 2024.
- Over the past 5 years, Guided Therapeutics' Total Current Liabilities (Quarter) stood at $5.7 million in 2021, then decreased by 14.49% to $4.9 million in 2022, then dropped by 1.23% to $4.8 million in 2023, then grew by 27.99% to $6.2 million in 2024, then increased by 5.12% to $6.5 million in 2025.
- Its Total Current Liabilities was $6.5 million in Q3 2025, compared to $6.4 million in Q2 2025 and $5.9 million in Q1 2025.